Medicare Issues Draft Local Coverage Determination for Natera's New Prospera™ Kidney Transplant Rejection Test

In March 2019, Natera, Inc. , a global leader in cell-free DNA testing, announced that Palmetto MolDx has issued draft local coverage determination (LCD) for use of the company's new Prospera donor-derived cell-free DNA (dd-cfDNA) test to detect active rejection in kidney transplant recipients.

QURE worked closely with Natera to generate the clinical utility evidence which was submitted to Palmetto for consideration. Our first publication from our collaboration with Natera can be read here.

Othman Ouenes